Alerts
PDF
Other content recommended for you
- Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016
- Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis
- Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations
- Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism
- The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice
- Comparative effectiveness of oral anticoagulants in everyday practice
- Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
- Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe
- Medical management of intracerebral haemorrhage
- Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial